'Primary endpoint cv death' presentation slideshows

Antiplatelet therapy for acute coronary syndrome treated with PCI: New developments

Antiplatelet therapy for acute coronary syndrome treated with PCI: New developments. Amber Malik Director Cath Lab Services Shaikh Zayed Hospital, Lahore. Platelet aggregation contributes to atherothrombosis which in turn is associated with Acute Coronary Syndromes

1.04k views • 82 slides

NSTEMI: GPIIB/IIIA Inhibitors & Emerging Antiplatelets : Where Do We Stand?

NSTEMI: GPIIB/IIIA Inhibitors & Emerging Antiplatelets : Where Do We Stand?. Rabih R. Azar , MD, MSc , FACC Director of Cardiovascular Research Hotel Dieu de France Hospital Associate Professor of Medicine Saint Joseph University School of Medicine Beirut, Lebanon.

754 views • 50 slides

448 views • 35 slides

TRITON-TIMI 38 AHA 2007 Orlando, Florida

TR ial to Assess I mprovement in T herapeutic Outcomes by O ptimizing Platelet Inhibitio N with Prasugrel. TRITON-TIMI 38 AHA 2007 Orlando, Florida.

560 views • 24 slides

TRITON-TIMI 38 AHA 2007 Orlando, Florida

TR ial to Assess I mprovement in T herapeutic Outcomes by O ptimizing Platelet Inhibitio N with Prasugrel. TRITON-TIMI 38 AHA 2007 Orlando, Florida.

395 views • 24 slides

ONTARGET

ONTARGET. Telmisartan (16.7%) noninferior; combination (16.3%) not superior to ramipril (16.5%) for primary endpoint (CV death, MI, stroke, heart failure) Greater incidence of hypotension in combination (4.8%) and telmisartan (2.7%) groups, compared with ramipril group (1.7%) (p < 0.001).

497 views • 1 slides